Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Post by FredTheVoiceon Mar 08, 2018 11:42am
143 Views
Post# 27683538

2018 = double for TH ?

2018 = double for TH ?
JFM1330 wrote: "InJanuary 2015, a bit more than three years ago, the SP of TH was at 0.36$. Since then it multiplied its value 26 times and there were sellers all the way up with consolidation periods. Now where will the SP be in a little bit more than three years? It will not be 26 times higher, but between three to six times higher is realistic"

You know, I'd be very very happy with a double in 2018, which I think is truly possible. I was thinking of all the good news coming: first sales; approbation for selling in Canada and Europe, investment groups starting loading big time in the next few weeks because the story will spread........and what again ? The price of the medication is great and dont forget, no competition, medication thats WANTED, NEEDED.........

Yes, I'LL be PATIENT. This story is great. 2018 SHOULD see TH double with the share price we have today........if this bull market goes on, if economy stays stable...

Good day to all.

FTV.

Bullboard Posts